Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RBP4 | P02753 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19779454 | 0.81 | POLB (0.72) | POLBKMT2AGAAALDH1A1LMNA | |
| SCHEMBL15646252 | 0.81 | POLB (0.66) | POLBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL19769013 | 0.78 | POLB (0.51) | POLBKMT2AMEN1GAAALDH1A1 | |
| SCHEMBL17109746 | 0.75 | ALDH1A1 (0.47) | POLBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL22096846 | 0.75 | NLRP3 (0.47) | POLBKMT2AGAAALDH1A1RAB9A | |
| SCHEMBL17117532 | 0.72 | LMNA (0.64) | POLBKMT2AALDH1A1LMNARAB9A | |
| SCHEMBL22096841 | 0.71 | ALDH1A1 (0.43) | KMT2AALDH1A1LMNARAB9APKM | |
| SCHEMBL22096863 | 0.69 | KMT2A (0.42) | KMT2AMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL10115709 | 0.69 | ALDH1A1 (0.45) | POLBKMT2AALDH1A1LMNARAB9A | |
| SCHEMBL13128818 | 0.69 | GPR119 (0.53) | PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | POLB 4367/4885KMT2A 4607/4885MEN1 110/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | POLB 4367/4885KMT2A 4607/4885MEN1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.